Wu Yiling

[Expert Profile] Wu Yiling, Chief Physician, Professor, Doctoral Supervisor, Academician of the Chinese Academy of Engineering, is an authoritative expert in the field of collaterals disease theory in China, working at Hebei Yiling Hospital. He has long been dedicated to clinical diagnosis, treatment, and scientific research of collaterals disease theory, cardiovascular and cerebrovascular diseases, arrhythmia, and chronic heart failure, and is the founder of the TCM collaterals disease theory.

[Education & Career] Professor Wu Yiling graduated from Nanjing College of Traditional Chinese Medicine, has long been engaged in TCM theory and clinical research, and pioneered the TCM collaterals disease theory. He serves as Dean of Hebei Yiling Pharmaceutical Research Institute and President of Hebei Yiling Hospital. He was elected as an Academician of the Chinese Academy of Engineering in 2009, and has held important academic positions including Chair of the Collaterals Disease Branch of the China Association of Chinese Medicine. He is an important leading figure in collaterals disease theory and cardiovascular and cerebrovascular disease prevention and treatment in China.

[Areas of Expertise] Professor Wu specializes in TCM diagnosis and treatment of cardiovascular and cerebrovascular diseases such as coronary heart disease, myocardial infarction, arrhythmia (ventricular premature beats, atrial fibrillation, etc.), and chronic heart failure. He has profound expertise in "collateral-unblocking" therapeutic methods under the guidance of collaterals disease theory, as well as Chinese herbal compound formulas for cardiovascular and cerebrovascular diseases. He excels at managing complex cases such as "recurrent angina pectoris and refractory arrhythmia" using collaterals disease theory, helping numerous cardiovascular and cerebrovascular patients improve symptoms and reduce cardiovascular events.

[Academic Achievements & Industry Contributions] The TCM collaterals disease theory created by Professor Wu has been listed as a key discipline direction of the National Administration of Traditional Chinese Medicine. A series of innovative Chinese medicines he led the research and development of, such as Tongxinluo, Shensong Yangxin, and Qili Qiangxin, have been confirmed through large-scale evidence-based studies to have definite efficacy for cardiovascular and cerebrovascular diseases, with research findings on Tongxinluo for acute myocardial infarction published in top international journals. He has led the development of collaterals disease-related diagnosis and treatment guidelines, actively promoted the internationalization of TCM collaterals disease theory and innovative Chinese medicines, and made outstanding contributions to TCM innovation and cardiovascular and cerebrovascular disease prevention and treatment in China.

[Clinical Practice & Outstanding Contributions] With decades of medical practice, Professor Wu has treated hundreds of thousands of cardiovascular and cerebrovascular disease patients, and the innovative Chinese medicines he developed have benefited numerous patients nationwide. He has received multiple national awards including the First Prize of the National Science and Technology Progress Award, trained a large number of collaterals disease and cardiovascular professionals, and is an authoritative expert with important influence in the field of traditional Chinese medicine in China.

[Honors & Reputation] Professor Wu Yiling serves as Dean of Hebei Yiling Pharmaceutical Research Institute and Chair of the Collaterals Disease Branch of the China Association of Chinese Medicine, among other academic positions. He was elected as an Academician of the Chinese Academy of Engineering in 2009, has presided over national-level major projects including the National Key R&D Program, and is an authoritative expert in the fields of collaterals disease theory and cardiovascular and cerebrovascular diseases in China. The collaterals disease theory he created has been listed as a key discipline direction of the National Administration of Traditional Chinese Medicine. A series of innovative Chinese medicines he led the research and development of, such as Tongxinluo, Shensong Yangxin, and Qili Qiangxin, have been confirmed through large-scale evidence-based studies to have definite efficacy for cardiovascular and cerebrovascular diseases, with research on Tongxinluo for acute myocardial infarction published in top international journals. He has received multiple national awards including the First Prize of the National Science and Technology Progress Award, and is an outstanding representative of TCM innovation.